ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,836.22
0.16%
Dow Jones
42,297.12
0.86%
US Dollar vs MXN
20.6514
0.17%
Brent Oil
79.855
-0.53%
Bitcoin
94,848.24
0.36%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) Noticias

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ASND
FechaHoraFuenteTítuloSímboloCompañía
12/01/202516:00GlobeNewswire Inc.Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
06/01/202507:30GlobeNewswire Inc.Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
30/12/202415:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
19/12/202407:30GlobeNewswire Inc.YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsNASDAQ:ASNDAscendis Pharma AS
16/12/202407:30GlobeNewswire Inc.New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26NASDAQ:ASNDAscendis Pharma AS
12/12/202415:01GlobeNewswire Inc.FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
10/12/202416:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
14/11/202415:01GlobeNewswire Inc.Ascendis Pharma Reports Third Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
14/11/202412:28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ASNDAscendis Pharma AS
07/11/202415:01GlobeNewswire Inc.Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024NASDAQ:ASNDAscendis Pharma AS
04/11/202406:00GlobeNewswire Inc.Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular DiseasesNASDAQ:ASNDAscendis Pharma AS
30/09/202407:30GlobeNewswire Inc.New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024NASDAQ:ASNDAscendis Pharma AS
30/09/202407:30GlobeNewswire Inc.Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
20/09/202415:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ASNDAscendis Pharma AS
19/09/202419:16GlobeNewswire Inc.Ascendis Pharma A/S Announces Pricing of Public Offering of ADSsNASDAQ:ASNDAscendis Pharma AS
18/09/202415:04GlobeNewswire Inc.Ascendis Pharma A/S Announces Proposed Public Offering of ADSsNASDAQ:ASNDAscendis Pharma AS
18/09/202415:01Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ASNDAscendis Pharma AS
16/09/202406:00GlobeNewswire Inc.Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to PlaceboNASDAQ:ASNDAscendis Pharma AS
13/09/202407:30GlobeNewswire Inc.Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024NASDAQ:ASNDAscendis Pharma AS
11/09/202416:37GlobeNewswire Inc.Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in AdultsNASDAQ:ASNDAscendis Pharma AS
04/09/202404:50IH Market NewsNvidia Subpoenaed by DOJ, Athira Pharma Shares Plunge 71% After Study Fails, Zscaler Falls 15% Post-EarningsNASDAQ:ASNDAscendis Pharma AS
03/09/202416:14GlobeNewswire Inc.Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementNASDAQ:ASNDAscendis Pharma AS
03/09/202416:06GlobeNewswire Inc.Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementNASDAQ:ASNDAscendis Pharma AS
03/09/202416:04GlobeNewswire Inc.Ascendis Pharma Reports Second Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
28/08/202407:30GlobeNewswire Inc.Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024NASDAQ:ASNDAscendis Pharma AS
13/08/202404:43IH Market NewsDell Stock Slide Offers Opportunities; Trump and Musk hold talks on X; GM Restructures China Operations, and MoreNASDAQ:ASNDAscendis Pharma AS
12/08/202406:00GlobeNewswire Inc.FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in AdultsNASDAQ:ASNDAscendis Pharma AS
04/07/202411:49PR Newswire (Canada)Pendopharm signe une entente de distribution exclusive avec Ascendis Pharma A/S pour TransCon MC PTH au CanadaNASDAQ:ASNDAscendis Pharma AS
04/07/202411:48PR Newswire (Canada)Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in CanadaNASDAQ:ASNDAscendis Pharma AS
24/06/202415:45GlobeNewswire Inc.Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024NASDAQ:ASNDAscendis Pharma AS
 Showing the most relevant articles for your search:NASDAQ:ASND

Su Consulta Reciente

BIT
UC4YBV
Unicredit Bank
BIT
1ADP
Automatic Data Processing
AMEX
ILI
Interleukin Genetics
NYSE
IEX
IDEX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados